v3.22.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (3,203,222) $ (3,460,310)
Stock-based compensation expense included in -    
General and administrative costs 763,766 1,506,836
Increase (decrease) in -    
Advances on research and development contract services 3,224 (246,435)
Prepaid insurance 8,574 (8,672)
Other prepaid expenses and current assets (30,313) (29,871)
Accounts payable and accrued expenses 146,743 (27,845)
Research and development contract liabilities 81,871 198,114
Net cash used in operating activities (2,229,357) (2,068,183)
Cash flows from financing activities:    
Proceeds from sale of common stock in direct equity offering, net of offering costs 5,141,384 3,689,761
Exercise of common stock warrants 17,100
Exercise of common stock options 101,000
Payment of deferred offering costs (10,467)
Net cash provided by financing activities 5,141,384 3,797,394
Cash:    
Net increase 2,912,027 1,729,211
Balance at beginning of period 4,823,745 5,069,266
Balance at end of period 7,735,772 6,798,477
Supplemental disclosures of cash flow information:    
Interest 3,121 2,944
Income taxes

Source